BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, Mégnin-chanet F, Kirova Y. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiotherapy and Oncology 2017;124:190-9. [DOI: 10.1016/j.radonc.2017.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Witt JS, Wisinski KB, Anderson BM. Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. Clin Breast Cancer 2021;21:120-7. [PMID: 34030859 DOI: 10.1016/j.clbc.2020.11.019] [Reference Citation Analysis]
2 Kirova Y, Tallet A, Aznar M, Loap P, Bouali A, Bourgier C. Radio-induced cardiotoxicity: From physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up. Cancer/Radiothérapie 2020;24:576-85. [DOI: 10.1016/j.canrad.2020.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Harbeck N. Advances in targeting HER2-positive breast cancer. Current Opinion in Obstetrics & Gynecology 2018;30:55-9. [DOI: 10.1097/gco.0000000000000431] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
4 Kawamoto T, Shikama N, Kurokawa C, Hara N, Oshima M, Sasai K. A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy. BMC Cancer 2021;21:109. [PMID: 33530984 DOI: 10.1186/s12885-021-07851-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. Oncogene 2020;39:2845-62. [PMID: 32034310 DOI: 10.1038/s41388-020-1193-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
6 Hu W, Wu X, Tang J, Zhao G, Xiao N, Zhang L, Li S. Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma: Findings of bioinformatic and experimental assays. J Cell Mol Med 2019;23:3505-11. [PMID: 30873755 DOI: 10.1111/jcmm.14248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Orecchia R, Rojas DP, Cattani F, Ricotti R, Santoro L, Morra A, Cambria R, Luraschi R, Dicuonzo S, Ronchi S, Surgo A, Dell' Acqua V, Veronesi P, De Lorenzi F, Fodor C, Leonardi MC, Jereczek-Fossa BA. Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation. Med Oncol 2018;35:39. [PMID: 29442173 DOI: 10.1007/s12032-018-1095-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Pons-Tostivint E, Alouani E, Kirova Y, Dalenc F, Vaysse C. Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?: Evidences, unresolved questions and a practical algorithm. Crit Rev Oncol Hematol 2021;157:103146. [PMID: 33227574 DOI: 10.1016/j.critrevonc.2020.103146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Mol Cancer Ther 2020;19:157-67. [PMID: 31597712 DOI: 10.1158/1535-7163.MCT-18-1302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ou D, Cao L, Xu C, Kirova Y, Chen J. Upfront brain radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast‐GPA 0‐2.0. Breast J 2019;25:1134-42. [DOI: 10.1111/tbj.13426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mocenigo M, Porchetta A, Rossetti M, Brass E, Tonini L, Puzzi L, Tagliabue E, Triulzi T, Marini B, Ricci F, Ippodrino R. Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples. ACS Sens 2020;5:3109-15. [PMID: 32909731 DOI: 10.1021/acssensors.0c01046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ben Dhia S, Loap P, Loirat D, Vincent-Salomon A, Cao K, Escalup L, Fourquet A, Kirova Y. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity]. Cancer Radiother 2021;25:424-31. [PMID: 33771453 DOI: 10.1016/j.canrad.2020.06.037] [Reference Citation Analysis]
13 Belgioia L, Desideri I, Errico A, Franzese C, Daidone A, Marino L, Fiore M, Borghetti P, Greto D, Fiorentino A; AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. Crit Rev Oncol Hematol 2019;133:163-70. [PMID: 30661652 DOI: 10.1016/j.critrevonc.2018.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
14 Piroth MD, Krug D, Sedlmayer F, Duma MN, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Souchon R, Strnad V, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? Strahlenther Onkol 2021;197:1-7. [PMID: 32737515 DOI: 10.1007/s00066-020-01667-z] [Reference Citation Analysis]
15 Loap P, Kirov K, Kirova Y. Cardiotoxicity in breast cancer patients treated with radiation therapy: From evidences to controversies. Crit Rev Oncol Hematol 2020;156:103121. [PMID: 33038628 DOI: 10.1016/j.critrevonc.2020.103121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Barati N, Razazan A, Nicastro J, Slavcev R, Arab A, Mosaffa F, Nikpoor AR, Badiee A, Jaafari MR, Behravan J. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Lett 2018;424:109-16. [PMID: 29580807 DOI: 10.1016/j.canlet.2018.03.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]